VIDEO: Consistent terminology may improve shared decision-making in NSCLC
Click Here to Manage Email Alerts
In this video, Nikki A. Martin, director of precision medicine initiatives at LUNGevity Foundation, discusses why her foundation, along with 20 other patient advocacy groups, are recommending the use of consistent terms in precision medicine.
Martin specifically addressed the need for consistent testing terms to lower the confusion of many lung cancer patients.
“In my role in precision medicine, I work on increasing non-small cell lung cancer patient access to biomarker testing,” she explained. “We all want to be using the same terms to talk about testing with our patients.”
LUNGevity, along with 20 patient advocacy groups, three professional societies and 18 industry partners, streamlined testing terminology, regardless of the cancer type. She advised clinicians to use biomarker testing when referring to testing for somatic or acquired mutations and other biomarkers. Additionally, when performing germline genetic testing, it should be noted if it is genetic testing when for an inherited mutation or genetic testing for inherited cancer risk.
“We want providers of all types to be also reflecting these same terms in their communications with patients,” Martin said.
Collapse
Healio Interview
Read more about
Click Here to Manage Email Alerts